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Aim: To assess serum myeloperoxidase (MPO) levels in autistic children with severe 
gastrointestinal (GI) disease and to test the hypothesis that there is an association between 
serum MPO concentration and inflammatory GI disease, including antineutrophil cytoplasmic 
antibodies (ANCA), previously seen in a subgroup of autistic children.
Subjects and methods: Serum from 40 autistic children with chronic digestive disease (most 
with ileo-colonic lymphoid nodular hyperplasia (LNH) and inflammation of the colorectum, small 
bowel and/or stomach), and 48 controls (12 age-matched autistic children with no GI disease, 
20 age-matched children without autism or GI disease, and 16 nonautistic individuals with no 
family history of autism) were tested using enzyme-linked immunosorbent assays designed to 
quantitate serum MPO levels. MPO serum concentration of autistic children with GI disease 
was compared to GI disease severity (including LNH and erythema) and presence of ANCA.
Results: We found that a significant number of autistic children with chronic digestive disease 
had low serum levels of MPO. However, there was no significant relationship between these 
levels and severity of GI disease, including the presence of ANCA.
Discussion: These results suggest a relationship between low MPO levels and GI disease seen 
in a subpopulation of autism spectrum disorders individuals. MPO concentration may therefore 
be a useful biomarker for GI disease in this group of autistic children.
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Introduction
Oxidants are thought to be key components of the neutrophil host defense system. 
Upon contact with a pathogen, particularly bacteria and fungi, neutrophils produce a 
respiratory burst characterized by intense uptake of oxygen. The resulting superoxide 
dismutates into hydrogen peroxide (H2O2). The toxicity of H2O2 to microbe pathogens is 
greatly enhanced by the heme enzyme myeloperoxidase (MPO), found in the azurophilic 
granules of neutrophils, which uses H2O2 to convert chloride (Cl−) into hypochlorous 
acid (HOCl). Although the exact mechanism is not completely understood, MPO also 
kills by directly chlorinating phagocytosed bacteria.1
In addition to killing bacteria, the products of the MPO-hydrogen peroxide-Cl system 
are believed to play a role in killing fungi, parasites, protozoa, viruses, tumor cells, natural 
killer (NK) cells, red cells, and platelets, and they may be involved in terminating the 
respiratory burst, because individuals with MPO deficiency have a prolonged reaction.2
Other functions of MPO include tyrosyl radical production, generation of tyrosine 
peroxide, mediation of the adhesion of myeloid cells via b2-integrins, and oxidation 
of serum lipoproteins.2Clinical and Experimental Gastroenterology 2009:2 86
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Autistic spectrum disorder (ASD) is a neurodevelopmental 
syndrome with onset prior to the age of 36 months. 
Diagnostic criteria consist of impairments in socialization and 
communication plus repetitive and stereotypic behaviors.3 
Traits strongly associated with autism include movement 
disorders and sensory dysfunctions.4 Although autism may be 
apparent soon after birth, many autistic children experience 
at least several months, up to a year or more in some cases, 
of normal development followed by regression, defined as 
loss of function or failure to progress.4–6
Children with ASD frequently have accompanying gas-
trointestinal (GI) symptoms7–9 and pathology, which includes 
inflammation of the GI tract.10–13 Many autistic children, 
particularly those with GI disease, have a higher propensity 
and related incidence of fungal infections.14,15
We previously reported that a significant number 
of autistic children with GI disease have antineutrophil 
cytoplasmic antibodies (ANCA; both antiproteinase 3 [anti-
PR3] and anti-MPO), and that there is a relationship between 
individuals with ANCA and severity of intestinal disease.16 
We have also reported that a significant number of autistic 
children with chronic digestive disease have anti-PR3 ANCA, 
low serum alpha-1 antitrypsin (AAT), and high serum PR3, 
which correlate with high severity of GI disease, suggest-
ing that high PR3 levels may be causing ANCA in autistic 
children with severe GI problems.17 Because of this, and the 
observation that a significant number of autistic children with 
GI disease have anti-MPO ANCA, we hypothesized that 
altered MPO levels might be associated with the production 
of ANCA to MPO.
The data presented here suggests that a significant number 
of autistic children with GI disease are MPO deficient, and, 
although no correlation was found between GI disease, ANCA, 
and MPO levels, this data suggests that MPO deficiency might 
be a biomarker for this subgroup of autistic children.
Materials and methods
ELisA to measure serum MPO levels 
(Kit - i.C.L. inc, newberg, OR 97132)
All reagents and specimens were equilibrated to room 
temperature before the assay was performed. One hundred 
microliters of a 1:10 dilution of the patient samples, calibra-
tors (15–1.875 ng/ml of affinity purified MPO), negative 
control of serum diluent alone, were added to the appropri-
ate microwells of a microculture plate (each well contained 
anti-MPO). Wells were incubated for 60 minutes (±5 min) 
at room temperature, then washed 4× with wash buffer. One 
hundred microliters of anti-human MPO conjugated with 
hydrogen peroxidase (HPO) was added to all microwells, 
incubated for 60 minutes (±5 min) at room temperature, 
then washed 4× with wash buffer. One hundred microliters 
of HPO substrate was then added to each microwell. After 
approximately 30 minutes at room temperature, the wells 
were read at 450 nm with an enzyme-linked immunosorbent 
assay (ELISA) reader (BioRad Laboratories, Inc., Hercules, 
CA, USA).
subjects and scoring of severity  
of Gi disease
Serum from autistic individuals with GI disease was obtained 
from the Thoughtful House, Austin, Texas.a All 40 children in 
this study with ASD (median age 6 years; range 2–16 years; 
34 male) having GI symptoms, were investigated by ileo-
colonoscopy. Esophagogastroduodenoscopy was performed 
on these patients, but only those with GI symptoms were 
part of this study.
A reproducible scoring system, similar to the Crohn’s 
Disease Endoscopic Index of Severity (CDEIS) was devel-
oped and used to evaluate this unique type of observed 
enterocolitis.
Macroscopic and histologic features for both upper and 
lower GI tract (such as ulcerations, erosions, lymphoid 
nodular hyperplasia [LNH], and erythema) were each 
scored out of 3: mild (1 point), moderate (2 points), or marked 
(3 points) for a total score out of 12. A point system was 
also developed for severity of LNH alone. Patients were 
scored according to mild (1 point), moderate (2 points), or 
marked (3 points) LNH in each area (upper and lower GI) 
for a maximum of 6 points. And finally, a point system was 
also developed for severity of erythema alone. Patients were 
scored according to mild (1 point), moderate (2 points), or 
marked (3 points) erythema in each area (upper and lower 
GI) for a maximum of 6 points.
Controls
Three control groups (total n = 48) were studied, including 
12 age- (mean 68 months), gender-(80% male), and 
diagnosis- (61% regressive onset) matched autistic children 
with no GI disease; 20 age- (mean 71 months) and gender- 
(75% male) matched children without autism or GI disease; 
16 nonautistic individuals with no family history of autism. 
Serum and medical history of age- and gender-matched 
aThe Thoughtful House Center for Children, founded in 2005 and located 
in Austin, Texas, is a collaboration between medical professionals and 
scientists seeking means to help children with autism spectrum disorders 
through a combination of medical care, education, and research.Clinical and Experimental Gastroenterology 2009:2 87
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controls were obtained from the Autism Genetic Resource 
Exchange (AGRE).b Serum from nonautistic individuals 
with no family history of autism was obtained from National 
Disease Research Interchange.c
serums
Experimental (Thoughtful House) and control (AGRE) 
serums were frozen at −70 °C immediately after collection 
and cell/serum separation, then stored at −70 °C until thawed 
for use in ELISAs.
statistics
Inferential statistics were derived from analysis of variance 
(ANOVA), Student’s t-test and odds ratios with 95% 
confidence intervals.
Results
Using the ELISA described above, autistic children with 
chronic digestive disease were tested for serum MPO levels. 
Results of a typical assay are shown in Figure 1. In each 
assay, MPO concentrations were determined by comparing 
experimental and control serum levels with MPO standards 
and negative controls (sample diluent alone) (Figure 2). 
For each assay, there were three or four replicate samples 
tested in each group (control and experimental), and each 
assay was repeated at least twice. We found that the MPO 
concentration of autistic children with GI disease (n = 40; 
m = 2.45 ng/ml ± 1.62) was significantly lower than three 
control groups; age/diagnosis-matched autistic children 
with no GI disease (n = 12; m = 14.35 ± 5.87; p  0.01); 
age/diagnosis-matched nonautistic children with no GI 
disease (n = 20; m = 13.33 ± 5.74; p  0.01) and individuals 
with no family history of autism (n = 16; m = 10.55 ± 5.71; 
p  0.01) (Figure 3).
Fifteen of the 40 autistic children with GI disease were 
categorized as having severe disease (score equal to or greater 
than 7 on total GI severity score criteria described above), 
six of 40 had severe LNH (score equal or greater than 4), 
and five of 40 had severe erythema (Table 1). Although 
most of the autistic children with GI disease had low MPO 
serum levels, there was no significant difference between 
MPO levels of these individuals and severity of GI disease, 
GI LNH (p = 0.4674) or erythema (p = 0.7806) (Table 3). 
Although those individuals with severe GI disease did have 
higher MPO levels, the difference was still not significant 
(p = 0.058). We also did not find a significant difference 
bThe Autism Genetic Resource Exchange (AGRE) is the first collaborative 
gene bank for the study of autism spectrum disorders and one of the world’s 
largest shared resources for the study of autism and related disorders, with 
a collection of over 900 well characterized multiplex and simplex families 
made available to the greater scientific community. Founded by Cure Autism 
Now (CAN) in 1997, AGRE is currently funded by the National Institute 
of Mental Health (NIMH) and Autism Speaks (AS), which merged with 
CAN in 2006.
cNational Disease Research Interchange, Philadelphia, PA, USA.
Figure 1 serum MPO concentration was measured in a typical ELisA. Five autistic children (A) with Gi disease, two autistic children with no Gi disease controls (C*), and 
three nonautistic children with no Gi disease controls (C**) were tested. Four replicate samples were tested for each individual.
Abbreviations: ELisA, enzyme-linked immunosorbent assay; Gi, gastrointestinal; MPO, myeloperoxidase.
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Figure 2 MPO serum concentration was established for each individual by testing and correlating to known standards of various concentrations of MPO (15–1.875 ng/ml) 
as well as a negative control (serum diluent alone).
Abbreviation: MPO, myeloperoxidase.
Figure 3 The mean ± SD MPO concentration (ng/ml) of 40 autistic children with chronic digestive disease (most with ileo-colonic LNH and inflammation of the colorectum, 
small bowel and/or stomach) (autistic Gi), and 48 controls (12 age matched autistic children with no Gi disease; control autistic, no Gi), 20 age-matched siblings of autistic 
children, without autism or Gi disease (control, no autism, no Gi), and 16 nonautistic individuals with no family history of autism (control no family history autism).
Abbreviations: Gi, gastrointestinal; Lnh, lymphoid nodular hyperplasia; MPO, myeloperoxidase; sD, standard deviation.
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between presence of ANCA and MPO serum concentration 
(p = 0.3718) (Table 2).
Discussion
Our results show that autistic children with severe GI disease 
have low serum levels of MPO, and, although our data does 
not demonstrate a relationship between these low levels 
and type or level of severity of GI disease or the presence 
of ANCA, the data suggests that low serum MPO may be a 
biomarker for this subgroup of autistic children.
In addition to facilitating the destruction of pathogens, 
MPO may play a role in the etiology of atherosclerosis. Clinical and Experimental Gastroenterology 2009:2 89
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Researchers have demonstrated that patients with stable 
coronary artery disease have an increased cardiovascular risk 
if plasma MPO levels are elevated.18 These high MPO levels 
result in high oxidative stress associated with an increase in 
lipid peroxidation. There is evidence to suggest that MPO 
deficiency may protect against cardiovascular disease.19
MPO-deficient neutrophils produce superoxide and 
H2O2 properly, but are unable to convert H2O2 to HOCl. 
As a consequence, neutrophil killing of some organisms 
is diminished early, but is normal late, as demonstrated by 
killing assays.20
MPO-deficient neutrophils are normally able to phago-
cytize most microbes. However, the ability of these cells 
to kill bacteria seems impaired. For organisms such as 
Staphylococcus aureus, Serratia species, and Escherichia 
coli, killing is initially impaired, but then reaches normal 
levels after a period of time. This suggests that an apparently 
slower, alternative mechanism of killing by these MPO-
deficient cells is functioning.21
In contrast, the capacity to kill certain fungi seems 
completely absent in MPO-deficient neutrophils. In vitro 
studies have shown that Candida albicans, C. krusei, 
C. stellatoidea, and C. tropicalis cannot be killed by 
MPO-deficient polymorphonuclear leucocytes (PMNs). 
In contrast, an MPO-independent mechanism can kill 
C. glabrata, C. parapsilosis, and C. pseudotropicalis. 
This leads to the conclusion that bacterial killing may not 
necessarily be a problem for patients with MPO deficiency, 
but the killing of certain fungi may be difficult, depending on 
the severity of the deficiency.22–24 Despite this, there are few 
case reports of serious infectious complications associated 
with MPO deficiency.25–27
There is quite a bit of evidence suggesting that oxidative 
stress28–32 and inflammation10–13 (particularly associated with 
the GI tract) are associated with autism. Studies have shown 
that MPO may serve as a biomarker for oxidative stress,33 
and MPO deficiency may also be associated with an increase 
in incidence of inflammation.34
Interestingly, MPO may also play a role in the 
downregulation of the inflammatory response by regulating 
NK cells, decreasing peptide binding to chemotactic receptors, 
and auto-oxidizing and inactivating products of PMNs, such 
as alpha1-proteinase inhibitor and chemotaxins.2
MPO generates numerous reactive oxidants and diffusible 
radical species35 that are capable of both initiating lipid 
peroxidation36,37 and promoting an array of post-translational 
modifications to target proteins, including halogenation, 
nitration, and oxidative cross-linking.38,39 Lipid peroxidation Clinical and Experimental Gastroenterology 2009:2 91
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Table 2 MPO concentration of autistic children with Gi disease with AnCA (anti-MPO or anti-MPO/anti-PR3; bold) and without AnCA 
are compared (p = 0.3718)
Autistic with  
GI Disease 
Mean O.D.  
anti-PR3 
Mean O.D 
anti-MPO 
 
Mean MPO 
ng/ml 
No MPO ANCA
Mean MPO  
ng/ml 
MPC ANCA
Diagnosis
RA 0.231 0.546 0.00
A 0.140 0.341 2.10
A 0.214 0.620 1.67
R-PDD 0.245 0.416 1.51
RA 0.253 0.553 1.44
RA 0.366 0.450 2.47
RA 0.466 0.833 2.13
RA 0.134 0.274 0.86
R-UD 0.251 0.351 5.91
RA 0.147 0.302 1.94
A 0.129 0.322 1.45
RA 0.121 0.286 3.63
PDD 0.181 0.317 1.71
A 0.189 0.341 4.19
A 0.401 0.630 1.03
RA 0.196 0.360 0.00
A 0.179 0.379 2.09
RA 0.175 0.329 2.87
R-PDD 0.443 0.539 2.47
A 0.576 0.629 3.51
R-PDD 0.278 0.529 8.22
RA 0.199 0.503 4.98
RA 0.544 0.504 5.05
A 0.218 0.387 3.94
RA 0.140 0.356 1.07
RA 0.259 0.463 2.58
R-ASP 0.099 0.225 1.08
A 0.174 0.457 2.97
PDD 0.197 0.361 2.34
R-PDD 0.274 0.506 1.53
RA 0.235 0.435 3.27
A 0.233 0.371 2.46
RA 0.482 0.566 1.61
A 0.136 0.284 3.22
RA 0.227 0.306 2.78
RA 0.221 0.537 2.60
RA 0.141 0.414 0.06
A 0.173 0.394 2.07
RA 0.166 0.313 2.02
RA 0.289 0.327 1.33
m 2.29 2.79
sd 1.28 2.19
sem 0.25 0.61
  ttest  p = 0.3718    
Abbreviations:   AnCA, antineutrophil cytoplasmic antibodies; Gi, gastrointestinal; MPO, myeloperoxidase.Clinical and Experimental Gastroenterology 2009:2 92
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Table 3 MPO concentration of autistic children with Gi disease with (bold) and without Lnh, with (bold) and without erythema and 
with (bold) and without severe total Gi disease are compared
Autistic With GI Disease  MPO MPO MPO MPO
  ng/ml ng/ml ng/ml ng/ml
Diagnosis LNH Eryth Total GI Total With LNH With eryth With total GI       
RA 2 0 5 0.00 Group MPO LNH
A 3 0 6 2.10 Mean 2.37 2.90
A 3 6 9 1.67 1.67 1.67 sD 1.62 1.63
R-PDD 1 0 3 1.51 sEM 0.28 0.67
RA 1 0 3 1.44 n 34 6
RA 2 2 6 2.47 t test
RA 4 3 8 2.13 2.13 2.13 2.13 p = 0.4674
RA 2 0 8 0.86 0.86
R-UD 4 2 8 5.91 5.91 5.91 Group MPO Erythema
RA 3 1 7 1.94 1.94 Mean 2.48 2.26
A 3 1 6 1.45 sD 1.70 0.99
RA 1 0 7 3.63 3.63 sEM 0.29 0.44
PDD 2 2 6 1.71 n 35 5
A 1 2 6 4.19 t test
A 3 5 10 1.03 1.03 1.03 p = 0.7806
RA 0 2 5 0.00
A 2 1 5 2.09 Group MPO Total GI Disease
RA 3 1 nA 2.87 Mean 2.07 3.13
R-PDD 5 0 nA 2.47 2.47 sD 1.25 2.10
A 4 4 11 3.51 3.51 3.51 3.51 sEM 0.26 0.56
R-PDD 3 1 8 8.22 8.22 n 24 14
RA 3 2 5 4.98 t test
RA 3 0 7 5.05 5.05 p = 0.058
A 3 2 8 3.94 3.94
RA 2 0 4 1.07
RA 3 0 4 2.58
R-ASP 2 1 6 1.08
A 3 4 6 2.97 2.97
PDD 2 1 4 2.34
R-PDD 2 1 4 1.53
RA 3 0 6 3.27
A 2 0 4 2.46
RA 3 2 6 1.61
A 0 0 nA 3.22
RA 3 0 5 2.78
RA 2 2 7 2.60 2.6
RA 2 0 3 0.06
A 4 0 7 2.07 2.07
RA 3 2 7 2.02 2.02
RA 6 0 10 1.33 1.33 1.33
m 2.45 2.90 2.26 3.13
    sd   1.62 1.63 0.99 2.10      
Abbreviations: Gi, gastrointestinal; Lnh, lymphoid nodular hyperplasia; MPO, myeloperoxidase.Clinical and Experimental Gastroenterology 2009:2 93
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has also been suggested to be a potential biomarker 
for autism.40–42
Some physicians, who have prescribed antifungals for 
autistic children with GI disease, have reported improvement 
in behaviors. We suggest that these improvements may be, 
at least in part, the result of MPO deficiency, which is 
acquired from antifungal administration and may result in 
reduced lipid peroxidation.
This report suggests that a subgroup of autistic children 
with GI disease have MPO deficiency. It is unclear whether 
this deficiency is acquired or inherited. Since MPO deficiency 
is associated with oxidative stress, increased inflammation, 
and propensity for fungal infections, all of which are mecha-
nisms also associated with autism, one could hypothesize that 
MPO deficiency may be directly linked with GI pathology 
seen in this subgroup of autistic children.
Although we did not see a relationship between MPO 
levels in the autistic children with GI disease and severity 
of GI disease, or presence of ANCA, this could be explained 
by the fact that such a large number of individuals in this 
group had very low levels of MPO, making small differences 
insignificant.
One possible reason for this MPO deficiency in this sub-
group is that children with GI disease, such as inflammatory 
bowel disease, as well as autistic children with GI disease, are 
often given anti-inflammatory drugs, which have been found 
to cause MPO deficiency.43–46 We did not have data available 
to investigate the possible relationship between antifungal 
therapy and MPO deficiency in this group of children with 
GI disease, but this area needs to be explored. If MPO defi-
ciency is temporarily acquired because of antifungal therapy, 
and many autistic children receiving antifungal therapy are 
improving with respect to behavior, then is that improvement, 
at least in part, do to less oxidative stress and/or reduction in 
inflammation resulting from MPO reduction?
In summary, we have discovered that a group of autistic 
children with GI disease have MPO deficiency. Since the pro-
duction of MPO is a major way that neutrophils are involved 
in antifungal defense, this deficiency may associate with 
increased fungal infection seen in many of these children. 
It is also possible, however, that anti-inflammatory and anti-
fungal drugs given to this group of autistic children may be 
causing or exasperating the deficiency and that these very 
low levels of MPO result in reduced oxidative stress and 
improved behavior.
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